Intranasal Protollin, a pathogen-associated molecular pattern (PAMP), shifts immune activation in early Alzheimer's disease by enhancing monocyte phagocytosis while reducing CD8+ T cell cytotoxicity in a Phase 1 trial. This immune recalibration addresses a core driver of neuroinflammation implicated in cognitive decline.
Key Points
- Protollin increases monocyte phagocytic capacity in early Alzheimer's patients
- CD8+ T cell cytotoxicity decreases following nasal administration
- Immune modulation achieved without systemic toxicity in Phase 1 cohort
Longevity Analysis
Alzheimer's pathology involves both insufficient clearance of amyloid and tau aggregates and excessive neuroinflammatory attack on healthy neural tissue. Protollin's dual mechanism—amplifying the immune system's cleanup capacity while dampening destructive cytotoxic responses—targets a critical imbalance in how the brain's defense system responds to neurodegeneration. For individuals in early disease stages, restoring this distinction between productive immunity and harmful inflammation may slow cognitive trajectory. The intranasal route delivers immune signaling directly to brain-proximal tissues, potentially offering efficacy at lower systemic doses.
Original published by Nature - npj Aging, by Panayota Kolypetri.